Evidence map›Paper›PMID 40698596›Full record

ArticleActa obstetricia et gynecologica Scandinavica2025

Placental growth factor before 11 weeks for screening of preterm preeclampsia: The PreMoM study.

Rocío López Mármol, José Alejandro Ávila Cabreja, Teresa de Haro Romero, Catalina de Paco Matallana, Olga Ocón Hernández, Otilia González-Vanegas, Pilar Carretero Lucena, María Paz Carrillo, Juan Luis Delgado, Valeria Rolle and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta obstetricia et gynecologica Scandinavica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rocío López MármolDepartment of Obstetrics and Gynecology, Hospital Universitario Virgen de las Nieves, Granada, Spain.ORCID 0000-0001-7757-7367
José Alejandro Ávila CabrejaFundación Pública Andaluza para la Investigación Biosanitaria Andalucía Oriental, Granada, Spain.
Teresa de Haro RomeroClinical Laboratory Management Unit, Hospital Universitario Clínico San Cecilio, Granada, Spain.ORCID 0000-0001-8647-2831
Catalina de Paco MatallanaDepartment of Obstetrics and Gynecology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.ORCID 0000-0002-0117-6388
Olga Ocón HernándezInstituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.ORCID 0000-0002-8113-3651
Otilia González-VanegasInstituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.ORCID 0000-0003-3917-5353
Pilar Carretero LucenaInstituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
María Paz CarrilloDepartment of Obstetrics and Gynecology, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Juan Luis DelgadoDepartment of Obstetrics and Gynecology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.ORCID 0000-0003-1687-0222
Valeria RolleBiostatistics and Clinical Research Unit, Hospital Universitario de Torrejón, Madrid, Spain.
Uzay GormusDepartment of Clinical Laboratory, Revvity Omics Sweden, Sollentuna, Sweden.
Liza OrahaDepartment of Clinical Laboratory, Revvity Omics Sweden, Sollentuna, Sweden.
María M GilDepartment of Obstetrics and Gynecology, Hospital Universitario de Torrejón, Madrid, Spain.ORCID 0000-0002-9993-5249
Francisca S MolinaInstituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.

Funding

Consejería de Salud y Consumo, Junta de Andalucía B-0006-2020Fundación BBVAiMaterna Foundation 2148Instituto de Salud Carlos III JR17/00027Instituto de Salud Carlos III PI18/01749Instituto de Salud Carlos III PI21/00803Revvity Omics SwedenRoche DiagnosticsThermo Fisher Scientific
6 · The paper itself

Abstract

introductionOur objective was to compare the predictive performance of the Fetal Medicine Foundation (FMF) competing-risk model for preterm preeclampsia (PE) screening using placental growth factor (PlGF) measurements obtained at 11-13 MATERIAL AND

methodsThis multicenter prospective cohort study included women with singleton pregnancies attending their routine first-trimester assessment (11

resultsThe study population comprised 3448 women, including 19 (0.55%) who developed preterm preeclampsia and 47 (1.36%) who developed term preeclampsia. At 10% SPR, the detection rates (adjusted for aspirin use) were highest for the model incorporating PlGF between 11 and 13

conclusionsPlGF measured before 11 weeks did not improve preterm PE screening performance. Due to the small number of cases, further validation is needed. Maternal and biophysical markers remain a viable alternative when PlGF is unavailable.

Indexed as

Placenta Growth FactorPre-EclampsiaAdultBiomarkersFemaleGestational AgeHumansPredictive Value of TestsPregnancyPregnancy Trimester, FirstProspective StudiesRisk AssessmentSpainBiomarkersPGF protein, humanPlacenta Growth Factorfirst pregnancy trimestermaternal serum screening testsplacenta growth factorpreeclampsia

Identifiers

PMID40698596
PMCPMC12451210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.